Ï M.Ð. åîïìïëïãåßôáé...

Boy Ðñéí áðü ìåñéêü êáéñü Ýíá áðü ôá Üôïìá ìå ôo ïðïßï åß÷á Ýñèåé óå óåîïõáëéêÞ åðáöÞ, ìïõ ôçëåöþíçóå êáé ìïõ åßðå “¸êáíá ôåóô ãéá AIDS êáé âãÞêå èåôéêü. Óõãíþìç!” ... êáé ìïõ êëåßíåé ôï ôçëÝöùíï.

Åêåßíç ôç óôéãìÞ ôï ìüíï ðïõ óêÝöôçêá Þôáí “êáé ðïëý ìïõ ðÝöôåé ðïõ ìå åíçìÝñùóå, ôï ëÜèïò Þôáí äéêü ìïõ ðïõ áðëÜ ðïôÝ äåí Ýèåóá ôï èÝìá ôçò ðñïöýëáîçò.”
ÌåôÜ áðü ðïëý óêÝøç êáé ìå äåäïìÝíï ôï üôé ìðïñåß êáé åãþ íá åßìáé ïñïèåôéêüò, áðïöÜóéóá íá ðÜù ãéá åîåôÜóåéò.
Íïìßæù üôé áõôü Þôáí Ýíá áðü ôá ëßãá ëïãéêÜ ðñÜãìáôá ðïõ Ý÷ù êÜíåé óôç æùÞ ìïõ ùò ôþñá.

Ìüëéò ÷ôÝò, ìïõ áíáêïéíþèçêå áðü ôïí ãéáôñü üôé ôåëéêÜ åßìáé êé åãþ ïñïèåôéêüò. Äåí ìðïñþ íá ðù üôé äåí Ýíïéùóá ôçí ãç íá ÷Üíåôáé êÜôù áðü ôá ðüäéá ìïõ.
Ðßóôåõá üôé ç ôý÷ç ìðïñåß íá åßíáé ðÜíôá ìå ôï ìÝñïò ìïõ. ËÜèïò! ºóùò äåí ðñÝðåé íá ôçí åß÷á ðñïêáëÝóåé ôüóï ðïëý.

Áðü ôçí Üëëç ðëåõñÜ óôçí ðåñßðôùóç ìïõ äåí ðéóôåýù üôé åßíáé èÝìá ôý÷çò Þ áôõ÷ßáò. ÁðëÜ Þôáí èÝìá åðéêßíäõíçò óõìðåñéöïñÜò.

¸ðñåðå íá ôï ðåñéìÝíù. ºóùò ôåëéêÜ äåí åß÷á áãáðÞóåé Þ ìÜëëïí äåí åß÷á óåâáóôåß ôïí åáõôü ìïõ üóï èá Ýðñåðå. Ôþñá Ýóôù êáé ìå ôïí äýóêïëï áõôü äñüìï Þñèå ç þñá íá äåßîù óôïí åáõôü ìïõ ðüóï ìå íïéÜæïìáé.

Ôï ðþò åßíáé íá æåéò ìå ôïí éü HIV äåí ìðïñþ íá ðù üôé ôï îÝñù áêüìç.

Óßãïõñá êÜèå äõóêïëßá óôç æùÞ èá ðñÝðåé íá áíôéìåôùðßæåôáé ìå áîéïðñÝðåéá êáé ü÷é íá áðïôåëåß åñãáëåßï åêìåôÜëëåõóçò “óõíáéóèçìÜôùí” ôùí áíèñþðùí ðïõ åßíáé ãýñù ìáò.
Ìçí ðåñéìÝíïõìå üôé ïé Üíèñùðïé ðïõ åßíáé ãýñù ìáò èá ìðïñïýí íá áíÝ÷ïíôáé óõíÝ÷åéá ôçí ìßæåñç êáé êëáøéÜñéêç óôÜóç ìáò. Äåí èá ìðïñÝóïõí íá ìáò âïçèÞóïõí áí åìåßò äåí ôï èÝëïõìå. Åßíáé óáí ôéò ïäçãßåò ãéá ôçí áóöÜëåéá åí ðôÞóç “Ðñþôá âÜëôå åóåßò ôç ìÜóêá ï÷õãüíïõ êáé ìåôÜ óôï ðáéäß”.

Áí äåßîåéò óåâáóìü êáé áãÜðç óôïí åáõôü óïõ ôüôå óßãïõñá èá ìðïñÝóïõí íá óåâáóôïýí êáé íá óå áãáðÞóïõí êáé ïé Üëëïé, ìå üôé êáé íá Ý÷åéò.

Óå ðñþôç öÜóç èÝëù íá áðïöýãù ôïí ðáíéêü êáé ôçí êïéíùíéêÞ ðåñéèùñéïðïßçóç. “Ôï üôé åßóáé ïñïèåôéêüò äåí óçìáßíåé üôé ðñÝðåé íá áðïìïíùèåßò, íá êëåéóôåßò óðßôé êáé íá ðÜøåéò íá æåéò”, Þôáí ôá ëüãéá ôùí äýï ðïëõôéìüôåñùí ÁÍÈÑÙÐÙÍ óôç æùÞ ìïõ. Ðéóôåýù üôé üðïéïò åßíáé áðïìïíùíïìÝíïò, åßíáé ãéáôß åî áñ÷Þò åß÷å èÝóåé ôïí åáõôü ôïõ óå áðïìüíùóç (ìðïñåß íá áêïýãåôáé óêëçñü, ßóùò êáé íá Ý÷ù êáé Üãíïéá).

ÈÝëù íá ïñêéóôþ óå ìÝíá üôé óå êáììßá ðåñßðôùóç äåí èá ãßíù äÝóìéïò ôùí óõíèçêþí ôçò æùÞò ìïõ.
Äåí ðéóôåýù üôé õðÜñ÷åé êÜôé ðïõ ìðïñåß íá ìå åìðïäßóåé íá ïíåéñåýïìáé ãéá ôï ìÝëëïí.

Åßìáé ìüëéò 29 åôþí êáé Ý÷ù ðïëëÜ íá êÜíù ìðñïóôÜ ìïõ áêüìá.




... 'Aëëåò éóôïñßåò ...



Lancet

Ðñüóöáôåò äçìïóéåýóåéò óôï ðåñéïäéêü The Lancet HIV

Optimised second-line regimens in the public health approach

Globally, most people receive antiretroviral therapy (ART) in programmes that follow the WHO-recommended public health approach, using a small number of standard regimens and simplified monitoring.1 A single standard regimen—dolutegravir (an integrase strand transfer inhibitor [INSTI]) with tenofovir disoproxil fumarate and lamivudine (both nucleoside reverse transcriptase inhibitors, [NRTIs])—is currently taken by the large majority of people on ART in these programmes, including those on second-line therapy (following previous failure of a non-NRTI regimen).

Prioritising HIV drug resistance testing according to risk

Tenofovir–lamivudine–dolutegravir (TLD) is recommended as an initial treatment regimen and a preferred optimised regimen for people living with HIV without a history of previous viral non-suppression, referred to as TLD in first-line therapy (TLD-1). For people living with HIV with persistent viral non-suppression, TLD largely replaced protease inhibitor-based regimens following efavirenz-based initial regimens, referred to as TLD in second-line therapy (TLD-2), as it is at least as effective, better tolerated, and more affordable.

Ending paediatric AIDS: time to close implementation gaps

WHO's global health sector strategies on HIV, conceived to guide the health sector in implementing strategically focused responses to achieve the goals of ending AIDS by 2030, target a reduction in the number of children aged 0–14 years newly infected with HIV from 150 000 in 2022 to 20 000 in 2025 and 15 000 in 2030.1 To track progress toward these targets, accurate estimations of the number of annual infections in children in each country is crucial. However, in many low-income and middle-income countries, where the burden of paediatric HIV is the highest, children are not systematically tested for HIV in programmes for the prevention of vertical transmission (PVT).

About us

Óôï hivaids.gr, öéëïîåíïýìå áöéëïêåñäþò ôï "Ðñüãñáììá Óõíåñãáóßáò" ÌïíÜäùí Ëïéìþîåùí ãéá ôçí áíÜðôõîç äéáäéêôõáêÞò ôñÜðåæáò êëéíéêþí ðáñáìÝôñùí. Ôï Ðñüãñáììá äçìéïõñãÞèçêå áðü Ýíáí ãéáôñü åéäéêü óôçí HIV ëïßìùîç ìå ôç óõììåôï÷Þ ôùí ÌïíÜäùí: Ðåñéóóüôåñá

% Áíáðçñßá êáé HIV

ÍÝïò êáíïíéóìüò

Åíéáßïò Ðßíáêáò Ðñïóäéïñéóìïý Ðïóïóôïý Áíáðçñßáò

Çìåñïëüãéï

@ Äéáýãåéá

ÄéáýãåéáÄé@ýãåéá

äéáöÜíåéá óôï êñÜôïò

ÄéáäéêôõáêÝò áíáñôÞóåéò äéïéêçôéêþí áðïöÜóåùí ãéá ôï HIV/AIDS

¸ñåõíá

Óáò Ý÷åé óðÜóåé ðïôÝ ôï ðñïöõëáêôéêü êáôÜ ôç äéÜñêåéá ìéáò åñùôéêÞò åðáöÞò;
Íáé
¼÷é
Äåí ÷ñçóéìïðïéþ

Åðéêïéíùíßá

Newsletter

Áíáêïéíþóåéò

×ñÞóéìåò ðëçñïöïñßåò